Minoxidil tablets contain the powerful antihypertensive agent minoxidil
which may produce serious adverse effects. It can cause pericardial
effusion occasionally progressing to temponade, and angina pectoris
may be exacerbated. Minoxidil should be reserved for hypertensive
patients who do not respond adequately to maximum therapeutic doses
of a diuretic and two other antihypertensive agents.
In experimental animals minoxidil caused several kinds of myocardial
lesions as well as other adverse cardiac effects (see CLINICAL
PHARMACOLOGY: Cardiac Lesions in Animals)
Minoxidil must be administered under close supervision. usually
concomitantly with therapeutic doses of a beta- adrenergic blocking
agent to prevent tachycardia and increased myocardial workload.
It must also usually be given with a diuretic frequently one acting
in the ascending limb of the loop of Henle, to prevent serious fluid
accumulation. Patients with malignant hypertension and those already
receiving guanethidine (see WARNINGS)
should be hospitalized when minoxidil is first administered so that
they can be monitored to avoid too rapid, or large orthostatic,
decreases in blood pressure.
Minoxidil tablets contain minoxidil, an antihypertensive peripheral vasodilator.
Minoxidil occurs as a white to off-white, crystalline powder. Soluble
in alcohol and propylene glycol; sparingly soluble in methanol; slightly
soluble in water; practically insoluble in chloroform, acetone and ethyl
acetate. The chemical name for minoxidil is 2,4-pyrimidine-diamine, 6-(1-piperidinyl)-,
It has the following molecular formula C9H15N5O
with a molecular weight of 209.25.
Minoxidil tablets for oral administration contain either 2.5 mg or 10
mg of minoxidil.
Minoxidil Tablets, USP 2.5 mg and 10 mg contain the following, inactive
ingredients: anhydrous lactose, docusate sodium, magnesium stearate, microcrystalline
cellulose, sodium, benzoate and sodium starch glycolate.